BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 17055096)

  • 1. Relationship between clinical factors and the incidence of toxicity after intra-arterial chemoradiation for head and neck cancer.
    van den Broek GB; Balm AJ; van den Brekel MW; Hauptmann M; Schornagel JH; Rasch CR
    Radiother Oncol; 2006 Nov; 81(2):143-50. PubMed ID: 17055096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose superselective intra-arterial cisplatin and concomitant radiation (RADPLAT) for advanced head and neck cancer.
    Balm AJ; Rasch CR; Schornagel JH; Hilgers FJ; Keus RB; Schultze-Kool L; Ackerstaff AH; Busschers W; Tan IB
    Head Neck; 2004 Jun; 26(6):485-93. PubMed ID: 15162349
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of treatment intensification on acute local toxicity during radiotherapy for head and neck cancer: prospective observational study validating CTCAE, version 3.0, scoring system.
    Palazzi M; Tomatis S; Orlandi E; Guzzo M; Sangalli C; Potepan P; Fantini S; Bergamini C; Gavazzi C; Licitra L; Scaramellini G; Cantu' G; Olmi P
    Int J Radiat Oncol Biol Phys; 2008 Feb; 70(2):330-7. PubMed ID: 17881148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiotherapy and concomitant intraarterial cisplatin (RADPLAT) for advanced squamous cell carcinomas of the head and neck.
    Rabbani A; Hinerman RW; Schmalfuss IM; Amdur RJ; Morris CG; Peters KR; Robbins KT; Mendenhall WM
    Am J Clin Oncol; 2007 Jun; 30(3):283-6. PubMed ID: 17551306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hyperfractionated, accelerated chemoradiation with concurrent mitomycin-C and cisplatin in locally advanced head and neck cancer, a phase I/II study.
    Hehr T; Classen J; Welz S; Ganswindt U; Scheithauer H; Koitschev A; Bamberg M; Budach W
    Radiother Oncol; 2006 Jul; 80(1):33-8. PubMed ID: 16875750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I study of dose-escalated chemoradiation with accelerated intensity modulated radiotherapy in locally advanced head and neck cancer.
    Guerrero Urbano T; Clark CH; Hansen VN; Adams EJ; A'Hern R; Miles EA; McNair H; Bidmead M; Warrington AP; Dearnaley DP; Harrington KJ; Nutting CM
    Radiother Oncol; 2007 Oct; 85(1):36-41. PubMed ID: 17709149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized phase 2 study of concomitant chemoradiotherapy using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancer.
    Haddad R; Sonis S; Posner M; Wirth L; Costello R; Braschayko P; Allen A; Mahadevan A; Flynn J; Burke E; Li Y; Tishler RB
    Cancer; 2009 Oct; 115(19):4514-23. PubMed ID: 19634161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Split course hyperfractionated accelerated radio-chemotherapy (SCHARC) for patients with advanced head and neck cancer: influence of protocol deviations and hemoglobin on overall survival, a retrospective analysis.
    Stadler P; Putnik K; Kreimeyer T; Sprague LD; Koelbl O; Schäfer C
    BMC Cancer; 2006 Dec; 6():279. PubMed ID: 17150114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of topical morphine for mucositis-associated pain following concomitant chemoradiotherapy for head and neck carcinoma.
    Cerchietti LC; Navigante AH; Bonomi MR; Zaderajko MA; Menéndez PR; Pogany CE; Roth BM
    Cancer; 2002 Nov; 95(10):2230-6. PubMed ID: 12412178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First-year quality of life assessment of an intra-arterial (RADPLAT) versus intravenous chemoradiation phase III trial.
    Ackerstaff AH; Balm AJ; Rasch CR; de Boer JP; Wiggenraad R; Rietveld DH; Gregor RT; Kröger R; Hilgers FJ
    Head Neck; 2009 Jan; 31(1):77-84. PubMed ID: 18972429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ototoxicity in a randomized phase III trial of intra-arterial compared with intravenous cisplatin chemoradiation in patients with locally advanced head and neck cancer.
    Zuur CL; Simis YJ; Lansdaal PE; Hart AA; Schornagel JH; Dreschler WA; Rasch CR; Balm AJ
    J Clin Oncol; 2007 Aug; 25(24):3759-65. PubMed ID: 17704425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and effectiveness of prophylactic gastrostomy tubes for head and neck cancer patients undergoing chemoradiation.
    Nguyen NP; North D; Smith HJ; Dutta S; Alfieri A; Karlsson U; Lee H; Martinez T; Lemanski C; Nguyen LM; Ludin A; Sallah S
    Surg Oncol; 2006 Dec; 15(4):199-203. PubMed ID: 17280829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors predictive of local disease control after intra-arterial concomitant chemoradiation (RADPLAT).
    Robbins KT; Doweck I; Samant S; Vieira F; Kumar P
    Laryngoscope; 2004 Mar; 114(3):411-7. PubMed ID: 15091211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapid superselective high-dose cisplatin infusion with concomitant radiotherapy for advanced head and neck cancer.
    Homma A; Furuta Y; Suzuki F; Oridate N; Hatakeyama H; Nagahashi T; Ushikoshi S; Asano T; Nishioka T; Shirato H; Fukuda S
    Head Neck; 2005 Jan; 27(1):65-71. PubMed ID: 15459915
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluating the role of prophylactic gastrostomy tube placement prior to definitive chemoradiotherapy for head and neck cancer.
    Chen AM; Li BQ; Lau DH; Farwell DG; Luu Q; Stuart K; Newman K; Purdy JA; Vijayakumar S
    Int J Radiat Oncol Biol Phys; 2010 Nov; 78(4):1026-32. PubMed ID: 20231073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk factors of ototoxicity after cisplatin-based chemo-irradiation in patients with locally advanced head-and-neck cancer: a multivariate analysis.
    Zuur CL; Simis YJ; Lansdaal PE; Hart AA; Rasch CR; Schornagel JH; Dreschler WA; Balm AJ
    Int J Radiat Oncol Biol Phys; 2007 Aug; 68(5):1320-5. PubMed ID: 17418969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aspiration rate following chemoradiation for head and neck cancer: an underreported occurrence.
    Nguyen NP; Frank C; Moltz CC; Vos P; Smith HJ; Bhamidipati PV; Karlsson U; Nguyen PD; Alfieri A; Nguyen LM; Lemanski C; Chan W; Rose S; Sallah S
    Radiother Oncol; 2006 Sep; 80(3):302-6. PubMed ID: 16890314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors associated with long-term dysphagia after definitive radiotherapy for locally advanced head-and-neck cancer.
    Caudell JJ; Schaner PE; Meredith RF; Locher JL; Nabell LM; Carroll WR; Magnuson JS; Spencer SA; Bonner JA
    Int J Radiat Oncol Biol Phys; 2009 Feb; 73(2):410-5. PubMed ID: 18635320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravenous amifostine during chemoradiotherapy for head-and-neck cancer: a randomized placebo-controlled phase III study.
    Buentzel J; Micke O; Adamietz IA; Monnier A; Glatzel M; de Vries A
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(3):684-91. PubMed ID: 16243440
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of tumor board recommendations on treatment outcome for locally advanced head and neck cancer.
    Nguyen NP; Vos P; Lee H; Borok TL; Karlsson U; Martinez T; Welsh J; Cohen D; Hamilton R; Nguyen N; Nguyen LM; Vinh-Hung V
    Oncology; 2008; 75(3-4):186-91. PubMed ID: 18841033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.